The combination of tarextumab – which inhibits Notch2/3 – and carboplatin/irinotecan suppresses SCLC tumor growth and delays relapse in SCLC allograft models, as well as in patient-derived xenografts in mice. Here, NOTCH2 is linked to small cell lung carcinoma.